Seronegative Arthritis Diagnosis and Treatment
Clinical Presentation and Diagnosis
- The American College of Rheumatology suggests that seronegative rheumatoid arthritis (SNRA) can manifest as oligoarthritis of large joints or symmetrical polyarthritis affecting small joints (MCPs, PIPs, wrists) 1, 2
- Ultrasonography should be used to confirm inflammatory activity when clinical assessment is uncertain, as recommended by the European League Against Rheumatism 3
- Reactive arthritis (Reiter's syndrome) is characterized by oligoarthritis of large joints (knees, ankles, wrists) that can present with conjunctivitis, urethritis, and back pain suggestive of sacroiliitis, according to the American College of Rheumatology 1, 2
- Psoriatic arthritis is a seronegative oligo or polyarthritis starting in medium/large joints, characterized by synovitis with tendon and entheses involvement, with or without erosions, as described by the National Psoriasis Foundation 1
Treatment Approach
- The American College of Rheumatology recommends methotrexate 15-25 mg/week as cornerstone therapy for seronegative rheumatoid arthritis 3
- The Mayo Clinic suggests triple DMARD therapy (methotrexate + sulfasalazine + hydroxychloroquine) for moderate to high disease activity 4, 3
- Seronegative patients respond better to abatacept or tocilizumab rather than rituximab after inadequate response to anti-TNF agents, according to the American College of Rheumatology 4, 3
- TNF inhibitors are the first-line biologic option (maximum 2 trials), as recommended by the European League Against Rheumatism 4
- Abatacept (CTLA4:Ig) is preferred for seronegative patients with inadequate anti-TNF response, according to the American College of Rheumatology 4, 3
- Tocilizumab (anti-IL-6R) is preferred for seronegative patients with inadequate anti-TNF response, as described by the National Institute of Arthritis and Musculoskeletal and Skin Diseases 4, 3
Monitoring and Reassessment
- The American College of Rheumatology recommends reassessing after 3-6 months of new treatment to evaluate efficacy 4, 3
- Maximum effect may not appear until 6 months in many patients, according to the European League Against Rheumatism 5
- If no improvement after 3-4 weeks of initial therapy, escalate treatment, as suggested by the Journal of Clinical Oncology 6
- Ultrasonography should be used when clinical assessment is challenging to confirm inflammatory activity, according to the European League Against Rheumatism 3
- Inflammatory markers (ESR, CRP) are usually highly elevated in immune-related arthritis, useful for differentiation, as described by the American College of Rheumatology 6, 2
- Disease activity scores (SDAI, CDAI, or DAS28-ESR) should be used for monitoring, as recommended by the European League Against Rheumatism 4, 7